A1 Refereed original research article in a scientific journal

Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016-17




AuthorsSandra Jackson, Teresa C T Peret, Thedi T Ziegler, Natalie J Thornburg, Terry Besselaar, Shobha Broor, Ian Barr, Elsa Baumeister, Mandeep Chadha, Malinee Chittaganpitch, Badarch Darmaa, Joanna Ellis, Rodrigo Fasce, Belinda Herring, Kadjo Herve, Siddhivinayak Hirve, Yan Li, Maria Pisareva, Ann Moen, Amel Naguib, Rakhee Palekar, Varsha Potdar, Marilda Siqueira, Florette Treurnicht, Almiro Tivane, Marietjie Venter, Niteen Wairagkar, Maria Zambon, Wenqing Zhang

Publication year2020

JournalInfluenza and Other Respiratory Viruses

Volume14

Issue6

First page 671

Last page677

Number of pages7

ISSN1750-2640

DOIhttps://doi.org/10.1111/irv.12771

Web address https://onlinelibrary.wiley.com/doi/10.1111/irv.12771

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/49605102


Abstract







Background:




External quality assessments (EQAs) for the molecular detection of
respiratory syncytial virus (RSV) are necessary to ensure the provision
of reliable and accurate results. One of the objectives of the pilot of
the World Health Organization (WHO) Global RSV Surveillance, 2016-2017,
was to evaluate and standardize RSV molecular tests used by
participating countries. This paper describes the first WHO RSV EQA for
the molecular detection of RSV.












Methods:




The WHO implemented the pilot of Global RSV Surveillance based on
the WHO Global Influenza Surveillance and Response System (GISRS) from
2016 to 2018 in 14 countries. To ensure standardization of tests, 13
participating laboratories were required to complete a 12 panel RSV EQA
prepared and distributed by the Centers for Disease Control and
Prevention (CDC), USA. The 14th laboratory joined the pilot late and
participated in a separate EQA. Laboratories evaluated a RSV rRT-PCR
assay developed by CDC and compared where applicable, other Laboratory
Developed Tests (LDTs) or commercial assays already in use at their
laboratories.












Results:




Laboratories performed well using the CDC RSV rRT-PCR in
comparison with LDTs and commercial assays. Using the CDC assay, 11 of
13 laboratories reported correct results. Two laboratories each reported
one false-positive finding. Of the laboratories using LDTs or
commercial assays, results as assessed by Ct values were 100% correct
for 1/5 (20%). With corrective actions, all laboratories achieved
satisfactory outputs.












Conclusions:




These findings indicate that reliable results can be expected from
this pilot. Continued participation in EQAs for the molecular detection
of RSV is recommended.








Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 12:02